Rhythm Pharmaceuticals (RYTM) Income from Continuing Operations (2016 - 2026)
Rhythm Pharmaceuticals' (RYTM) quarterly Income from Continuing Operations came in at 55594000.0 in Q1 2026, down 12.27% year-on-year from 63369635.19 in Q1 2025, and down 17.03% on a QoQ basis from 47505000.0 in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 11 years of Income from Continuing Operations data on file, last reported at 55594000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 12.27% year-over-year to 55594000.0 in Q1 2026; TTM through Mar 2026 was 202598000.0, a 20.04% decrease from a year earlier, with the FY2025 full-year figure at 196539000.0, up 24.58% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 55594000.0, down from 47505000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for RYTM reached as high as 32282000.0 in Q2 2024 and fell as low as 141372000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 51972058.82 across 5 years, with a median of 46703000.0 in 2023.
- Across the five-year window, Income from Continuing Operations slumped 226.48% in 2022 and surged 64.97% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 42493000.0 in 2022, then advanced by 2.02% to 41633000.0 in 2023, then fell by 4.07% to 43328000.0 in 2024, then retreated by 9.64% to 47505000.0 in 2025, then slipped by 17.03% to 55594000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 55594000.0 in Q1 2026, 47505000.0 in Q4 2025, and 52904000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Rhythm Pharmaceuticals | 6.98 Bn | 6.64 Bn | 52.96 Mn | -55.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.59 Mn |
| Dec 31, 2025 | -47.51 Mn |
| Sep 30, 2025 | -52.90 Mn |
| Jun 30, 2025 | -46.60 Mn |
| Mar 31, 2025 | -49.52 Mn |
| Dec 31, 2024 | -43.33 Mn |
| Sep 30, 2024 | -43.64 Mn |
| Jun 30, 2024 | -32.28 Mn |
| Mar 31, 2024 | -141.37 Mn |
| Dec 31, 2023 | -41.63 Mn |
| Sep 30, 2023 | -44.16 Mn |
| Jun 30, 2023 | -46.70 Mn |
| Mar 31, 2023 | -52.18 Mn |
| Dec 31, 2022 | -42.49 Mn |
| Sep 30, 2022 | -40.86 Mn |
| Jun 30, 2022 | -47.42 Mn |
| Mar 31, 2022 | -55.33 Mn |
| Dec 31, 2021 | -53.83 Mn |
| Sep 30, 2021 | -38.32 Mn |
| Jun 30, 2021 | -35.39 Mn |